Mangalam Drugs & Organics rose 2.66% to Rs 198.40 at 11:30 IST on BSE after net profit rose 18.63% to Rs 6.56 crore on 17.52% growth in net sales to Rs 82.91 crore in Q4 March 2017 over Q4 March 2016.
The result was announced after market hours yesterday, 8 May 2017.Meanwhile, the BSE Sensex was up 32.18 points, or 0.11%, to 29,958.33. The BSE Small-Cap index was up 91.93 points, or 0.59% to 15,554.51.
On the BSE, so far 44,000 shares were traded in the counter, compared with average daily volumes of 40,436 shares in the past one quarter. The stock had hit a high of Rs 202 and a low of Rs 196 so far during the day. The stock hit a 52-week high of Rs 239.90 on 10 May 2016. The stock hit a 52-week low of Rs 122.90 on 22 November 2016.
The stock had outperformed the market over the past one month till 8 May 2017, rising 31.55% compared with 0.74% rise in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 22.58% as against Sensex's 5.61% rise.
The small-cap company has equity capital of Rs 15.83 crore. Face value per share is Rs 10.
Mangalam Drugs & Organics manufactures active pharma ingredients (APIs), intermediates and specialty chemicals.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
